Serial Passaging of the Human Rotavirus CDC-9 Strain in Cell Culture Leads to Attenuation: Characterization from
oral vaccines
rotavirus
vaccine
virus adaptation
virus attenuation
Journal
Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724
Informations de publication
Date de publication:
16 07 2020
16 07 2020
Historique:
received:
07
05
2020
accepted:
12
05
2020
pubmed:
29
5
2020
medline:
20
11
2020
entrez:
29
5
2020
Statut:
epublish
Résumé
Live oral rotavirus vaccines have been developed by serial passaging in cell culture and found to be safe in infants. However, mechanisms for the adaptation and attenuation of rotavirus vaccines are not fully understood. We prepared a human rotavirus vaccine strain, CDC-9 (G1P[8]), which when grown in MA104 cells to passage 11 or 12 (P11/P12) had no nucleotide or amino acid sequence changes from the original virus in stool. Upon adaptation and passages in Vero cells, the strain underwent five amino acid changes at P28 and one additional change at P44/P45 in the VP4 gene. We performed virologic, immunological, and pathogenic characterization of wild-type CDC-9 virus at P11/P12 and its two mutants at P28 or P44/P45 using
Identifiants
pubmed: 32461318
pii: JVI.00889-20
doi: 10.1128/JVI.00889-20
pmc: PMC7375378
pii:
doi:
Substances chimiques
Capsid Proteins
0
Rotavirus Vaccines
0
VP4 protein, Rotavirus
0
Vaccines, Attenuated
0
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2020 American Society for Microbiology.
Références
J Gen Virol. 2014 Aug;95(Pt 8):1723-1733
pubmed: 24814927
J Virol. 2020 Feb 28;94(6):
pubmed: 31896593
Hum Vaccin. 2010 Mar 23;6(3):
pubmed: 20009519
Virology. 1991 Mar;181(1):295-304
pubmed: 1847258
J Virol. 2013 Aug;87(15):8307-16
pubmed: 23698306
J Exp Med. 1954 Jun 1;99(6):551-76
pubmed: 13163327
N Engl J Med. 1968 Feb 1;278(5):227-32
pubmed: 4169706
J Virol. 2014 Jan;88(1):41-53
pubmed: 24131713
Am J Dis Child. 1960 Dec;100:942-6
pubmed: 13751828
Expert Rev Vaccines. 2009 May;8(5):607-18
pubmed: 19397417
Lancet. 2014 Jun 21;383(9935):2136-43
pubmed: 24629994
Am J Dis Child. 1969 Aug;118(2):178-85
pubmed: 5794813
Clin Diagn Lab Immunol. 1999 Sep;6(5):690-5
pubmed: 10473519
Expert Rev Vaccines. 2012 May;11(5):609-28
pubmed: 22827246
J Virol. 2007 Apr;81(8):3904-12
pubmed: 17267507
N Engl J Med. 1966 Sep 15;275(11):569-74
pubmed: 4958645
J Virol. 1993 May;67(5):2448-55
pubmed: 8386262
Clin Diagn Lab Immunol. 2003 Nov;10(6):995-1001
pubmed: 14607858
J Virol. 2006 May;80(10):4820-32
pubmed: 16641274
Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12283-7
pubmed: 25136134
J Virol. 2011 Mar;85(6):2686-94
pubmed: 21191030
J Virol. 2005 May;79(9):5428-36
pubmed: 15827157
J Virol. 1997 Aug;71(8):6267-70
pubmed: 9223531
J Virol. 2002 Jan;76(1):41-57
pubmed: 11739670
Vaccine. 1998 Feb;16(4):381-7
pubmed: 9607059
Clin Infect Dis. 2009 Jan 15;48(2):222-8
pubmed: 19072246
Biken J. 1975 Mar;18(1):25-33
pubmed: 167707
Nat Rev Immunol. 2005 May;5(5):375-86
pubmed: 15864272
J Virol. 1997 Jul;71(7):5115-23
pubmed: 9188578
Vaccine. 2012 Apr 27;30 Suppl 1:A114-21
pubmed: 22520120
Front Immunol. 2017 Dec 11;8:1758
pubmed: 29312301
N Engl J Med. 1966 Sep 15;275(11):575-80
pubmed: 5331945
N Engl J Med. 1960 Jul 28;263:153-9
pubmed: 13820246
J Virol. 1986 Dec;60(3):972-9
pubmed: 3023685
Proc Soc Exp Biol Med. 1966 Dec;123(3):768-75
pubmed: 4163620
Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4114-9
pubmed: 15741273
Virology. 1995 May 10;209(1):274-80
pubmed: 7747480
J Virol. 2009 May;83(10):4942-51
pubmed: 19244315
J Virol. 2007 May;81(9):4473-81
pubmed: 17301153